$bluebird bio(BLUE.US)$Watching Bluebird Bio; Shares Spike Higher As Traders Circulating Unconfirmed Rumor Suggesting "Lyfgenia Is Among 8 New Therapies In The Running To Receive NTAP Designations At The Start Of FY25. The Emphasis On Supporting Access For SCD Therapies Across HHS Leaves Little Doubt That The New Therapy Will Qualify"
$bluebird bio(BLUE.US)$ NEWS bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) bluebird bio, Inc. (BLUE) approved inducement grants of 102,700 RSUs to twelve new employees. The RSUs vest equally over four years, in line with NASDAQ rules.
$bluebird bio(BLUE.US)$Accounting errors they say caused the restatement! So who pays for people’s losses because they went with the original numbers? Hehehe
1
4
举报
Jaguar8 :
They should pay. I see lawsuits here haha
$bluebird bio(BLUE.US)$bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance - Cash runway through Q1 2026 following announcement of a $175 million term loan facility with Hercules Capital - - 9 patient starts to date in 2024 (7 ZYNTEGLO, 2 SKYSONA); 85 to 105 patient starts anticipated across the portfolio in 2024 - - First government outcomes-based agreement for sickle cell disease signed with Michigan Medicaid - - 62 qualified...
bluebird bio股票讨论区
NEWS
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio, Inc. (BLUE) approved inducement grants of 102,700 RSUs to twelve new employees. The RSUs vest equally over four years, in line with NASDAQ rules.
- Cash runway through Q1 2026 following announcement of a $175 million term loan facility with Hercules Capital -
- 9 patient starts to date in 2024 (7 ZYNTEGLO, 2 SKYSONA); 85 to 105 patient starts anticipated across the portfolio in 2024 -
- First government outcomes-based agreement for sickle cell disease signed with Michigan Medicaid -
- 62 qualified...
暂无评论